Chia Tai Enterprises International Limited (3839.HK)
HKD 1.6
(0.0%)
HKD 1.6
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 33.76 Million USD | -13.84% |
| 2022 | 39.18 Million USD | 12.74% |
| 2021 | 34.76 Million USD | 39.61% |
| 2020 | 24.89 Million USD | -13.99% |
| 2019 | 28.94 Million USD | 6.22% |
| 2018 | 27.25 Million USD | 23.63% |
| 2017 | 22.04 Million USD | -29.39% |
| 2016 | 31.21 Million USD | -8.07% |
| 2015 | 33.96 Million USD | -9.89% |
| 2014 | 37.68 Million USD | 2.49% |
| 2013 | 36.77 Million USD | -7.18% |
| 2012 | 39.61 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 8.51 Million USD | 7.71% |
| 2024 Q2 | 9.47 Million USD | 11.39% |
| 2023 Q2 | 8.4 Million USD | -16.06% |
| 2023 Q4 | 7.9 Million USD | 5.97% |
| 2023 FY | 33.76 Million USD | -13.84% |
| 2023 Q3 | 7.45 Million USD | -11.25% |
| 2023 Q1 | 10 Million USD | -3.55% |
| 2022 FY | 39.18 Million USD | 12.74% |
| 2022 Q3 | 9.68 Million USD | -1.66% |
| 2022 Q4 | 10.37 Million USD | 7.12% |
| 2022 Q1 | 9.27 Million USD | -7.05% |
| 2022 Q2 | 9.85 Million USD | 6.18% |
| 2021 Q1 | 8.8 Million USD | 41.94% |
| 2021 FY | 34.76 Million USD | 39.61% |
| 2021 Q4 | 9.98 Million USD | 19.32% |
| 2021 Q3 | 8.36 Million USD | 9.86% |
| 2021 Q2 | 7.61 Million USD | -13.48% |
| 2020 Q2 | 6.27 Million USD | -4.05% |
| 2020 Q4 | 6.2 Million USD | 5.28% |
| 2020 Q3 | 5.88 Million USD | -6.11% |
| 2020 FY | 24.89 Million USD | -13.99% |
| 2020 Q1 | 6.53 Million USD | -12.37% |
| 2019 Q2 | 7.61 Million USD | 2.86% |
| 2019 Q1 | 7.4 Million USD | -14.71% |
| 2019 FY | 28.94 Million USD | 6.22% |
| 2019 Q4 | 7.46 Million USD | 15.3% |
| 2019 Q3 | 6.47 Million USD | -15.04% |
| 2018 Q4 | 8.68 Million USD | 45.42% |
| 2018 Q2 | 5.56 Million USD | -21.0% |
| 2018 Q1 | 7.04 Million USD | 6.79% |
| 2018 FY | 27.25 Million USD | 23.63% |
| 2018 Q3 | 5.96 Million USD | 7.3% |
| 2017 Q4 | 6.59 Million USD | 25.0% |
| 2017 Q2 | 4.22 Million USD | -28.91% |
| 2017 Q1 | 5.94 Million USD | -24.8% |
| 2017 FY | 22.04 Million USD | -29.39% |
| 2017 Q3 | 5.27 Million USD | 24.76% |
| 2016 Q3 | 7.8 Million USD | -10.48% |
| 2016 Q2 | 8.72 Million USD | 28.52% |
| 2016 Q1 | 6.78 Million USD | -16.89% |
| 2016 Q4 | 7.9 Million USD | 1.31% |
| 2016 FY | 31.21 Million USD | -8.07% |
| 2015 FY | 33.96 Million USD | -9.89% |
| 2015 Q4 | 8.16 Million USD | 0.32% |
| 2015 Q3 | 8.13 Million USD | -8.98% |
| 2015 Q2 | 8.94 Million USD | 2.57% |
| 2015 Q1 | 8.71 Million USD | -14.19% |
| 2014 Q4 | 10.15 Million USD | 18.67% |
| 2014 Q3 | 8.56 Million USD | -9.72% |
| 2014 Q2 | 9.48 Million USD | 0.0% |
| 2014 Q1 | 9.48 Million USD | 0.0% |
| 2014 FY | 37.68 Million USD | 2.49% |
| 2013 FY | 36.77 Million USD | -7.18% |
| 2012 FY | 39.61 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | 79.833% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 99.482% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -17.329% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | 91.448% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 194.84% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | 93.875% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 97.806% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | 92.835% |
| PuraPharm Corporation Limited | 216.62 Million HKD | 84.413% |
| SSY Group Limited | 3.48 Billion HKD | 99.032% |
| JBM (Healthcare) Limited | 319.41 Million HKD | 89.429% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 94.558% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 99.922% |